Who owns Editas medicine?
Table of Contents
Who owns Editas medicine?
Editas Medicine
| Type | Public company |
|---|---|
| Founders | Jennifer Doudna, Feng Zhang, George Church (geneticist), David R. Liu, J. Keith Joung |
| Headquarters | Cambridge, Massachusetts , United States |
| Number of locations | 2 |
| Key people | Gilmore O’Neill (President and CEO) |
Is Editas public?
Our common stock is traded on the NASDAQ Global Market under the ticker EDIT. Our initial public offering took place on February 3, 2016. Who were the managing underwriters for the Editas’ IPO? The underwriters for the IPO were Morgan Stanley, J.P. Morgan, Cowen and Company and JMP Securities.
Is Editas undervalued?
As for valuations, a comparison with peers reveals that at a trailing EV/Sales multiple of just 24.97x, the stock is significantly undervalued.
What does Editas company do?
Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world.
Is Editas Medicine a good stock to buy?
Of course Editas Medicine may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
Why is Editas stock down?
However, the main factor behind Editas’ decline this week appears to be the overall sell-off in biotech stocks.
When did Editas go public?
February 3 , 2016
The shares began trading on the NASDAQ Global Select Market on February 3 , 2016.
Will Editas Medicine stock go up?
Based on 12 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $22.27 with a high forecast of $40.00 and a low forecast of $8.00. The average price target represents a 76.89% change from the last price of $12.59.
Should I sell Editas stock?
Out of 7 analysts, 2 (28.57%) are recommending EDIT as a Strong Buy, 2 (28.57%) are recommending EDIT as a Buy, 2 (28.57%) are recommending EDIT as a Hold, 0 (0%) are recommending EDIT as a Sell, and 1 (14.29%) are recommending EDIT as a Strong Sell. What is EDIT’s earnings growth forecast for 2022-2024?
Is Editas stock a good buy?
Out of 7 analysts, 2 (28.57%) are recommending EDIT as a Strong Buy, 2 (28.57%) are recommending EDIT as a Buy, 2 (28.57%) are recommending EDIT as a Hold, 0 (0%) are recommending EDIT as a Sell, and 1 (14.29%) are recommending EDIT as a Strong Sell.
Will Editas go up?
The 14 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 27.50, with a high estimate of 80.00 and a low estimate of 8.00. The median estimate represents a +89.13% increase from the last price of 14.54.
How much cash does Editas have?
Editas said it has $566.4 million in cash as of March 31, compared to $619.9 in the prior quarter. It said that was enough cash to fund operating expenses into early 2024.
Is Editas medicine a buy?
Cramer’s lightning round: Editas Medicine is not a buy.
What company owns the patent to CRISPR?
(NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, Ph. D. (collectively, “UC”), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome editing technology, were granted U.S. Patent No.
What is doudna doing now?
As of 2020, Doudna was located at the University of California, Berkeley, where she directs the Innovative Genomics Institute, a collaboration between Berkeley and UCSF; holds the Li Ka Shing Chancellor’s Professorship in Biomedicine and Health; and is the chair of the Chancellor’s Advisor Committee on Biology.
Is Editas a good stock?
Editas Medicine has received a consensus rating of Hold. The company’s average rating score is 2.22, and is based on 4 buy ratings, 3 hold ratings, and 2 sell ratings.
Does EDIT 101 work?
Previously, Editas Medicine completed dosing of all adult cohorts in its BRILLIANCE study and announced preliminary EDIT-101 clinical results demonstrated a favorable safety profile and encouraging signals of clinical benefit.
Who is the leader in CRISPR technology?
The three leading gene-editing companies looking at commercialising CRISPR-based therapeutics are CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine.
